Accelerating Breakthrough Discoveries into Medicines

Ferozrpapa from OptiKira talking in a lab

Scientists in lab examining solution

 

From research institutions to patients

 

BioMotiv is the mission-driven development company associated with The Harrington Project for Discovery & Development, a national initiative centered at University Hospitals Cleveland Medical Center. The company’s focus is accelerating breakthrough discoveries from research institutions into therapeutics for patients.

Led by experienced industry professionals

BioMotiv has a capable and connected management team, advisory board, and Board that oversee the development, funding, active management, and partnering of the portfolio of therapeutic products.

Pharmaceutical Expertise

Our leadership and portfolio teams are well-versed in translational science, with deep pharmaceutical experience having supported the advancement of numerous programs into clinical development and into the marketplace.

Deep Business Networks

Through their careers, the company’s leadership team and advisory board members have developed broad relationships in the investment and pharmaceutical industries that are available to be accessed by BioMotiv companies.

Partnered with leading companies

News

BioMotiv Expands with a New Office in Philadelphia

On Wednesday, April 25, BioMotiv colleagues and friends gathered to celebrate the opening of a new Philadelphia office located in The Innovation Hub, a collaborative life sciences space managed by Militia Hill Ventures.

BioMotiv Expands with a New Office in Philadelphia

On Wednesday, April 25, BioMotiv colleagues and friends gathered to celebrate the opening of a new Philadelphia office located in The Innovation Hub, a collaborative life sciences space managed by Militia Hill Ventures.

OptiKira Achieves Significant Proof-of-Principle Milestone

OptiKira, LLC, a privately-held biotechnology startup developing drugs that inhibit the unfolded protein response (UPR) with applications in a variety of diseases, including retinitis pigmentosa, type I diabetes, idiopathic pulmonary fibrosis (IPF), amyotrophic lateral sclerosis (ALS), and immuno-oncology announced today that it achieved a significant proof-of-principle milestone.

SapVax Founder Recognized by Royal Society of Chemistry

Margaret Brimble, CNZM, FRSNZ, PhD, co-scientific founder of SapVax and Distinguished Professor & Director, Medicinal Chemistry at The University of Auckland, has been awarded the 2018 George and Christine Sosnovsky Award in Cancer Therapy from the Royal Society of...